PulmoBioMed Ltd.
PulmoBioMed Ltd. empowers clinicians and researchers to retrieve liquid and gas samples from the deep lung, entirely non-invasively, and without any contamination, to quickly, directly, and specifically indentify the cause of lung disease.
Our first project, PBM-HALE™, is the only hand-held, point-of-care medical device that supplies a highly reproducible deep lung fluid sample, as quickly as 2 mins and at a 40x lower cost.
Patients simply exhale; clinicians choose what to measure.
PulmoBioMed stands at the forefront of advancing non-invasive deep lung sampling, leveraging insights from a diverse range of disciplines. Our vision is to become the trusted pioneers in personalised lung disease diagnosis and monitoring in the clinic and at home, as well as empowering every patient and clinician to achieve optimal lung health by accessing all classes of biomarkers in the lung.
2019
Start Date
Newcastle Upon Tyne
Location
7
Employees
£500K
Grants
£150K
Equity
The Journey
PulmoBioMed’s team has received support from iCURe NxNW to conduct primary market validation research in May 2019. Attending the American Thoracic Society, BIO Convention, and Biodefence Congress in the USA initiated deep discussions with Key Opinion Leaders at Harvard, National Jewish Health, Yale, and Imperial College; commercial utility discussions with companies such as Bosch, Roche Diagnostics, Medtronic, Illumina, and Clement Clarke International Ltd were then conducted across the USA and EU; and specialist applications were explored with stakeholders such as ARA, [dstl], and Lawrence Livermore National Laboratory. The outcomes of over 141 meaningful conversations presented to an InnovateUK expert panel (July 2019) resulted in a strong recommendation for commercialization via spinout, and a competitive bid for a £299k InnovateUK Follow On funding bid was won in January 2020.
Pivoting to a COVID-19 clinical utility study in February 2020, PulmoBioMed emerged from the pandemic as the only company whose breath-based screening solution identified 100% of symptomatic cases, without false positives. The simultaneous capacity to assess patient lung inflammation status, even when operating in resource limited settings like a Brazilian favela, confirmed fit for point of need use, and utility across the spectrum of lung disease.
Assembling a world-class management team, we closed a 40% oversubscribed first investment round in 2023 to bring PBM-HALETM to clinical and primary healthcare use. The company registered with the US FDA as a medical device establishment in July 2024 and launched its core product at the European Respiratory Society Conference and Expo in September 2024.”
Contact Form
Idea for a contamination-free breath sampler
EBC sample collector (PBM-Hale™) patent granted
ICURe NXNW Cohort C completed
PulmoBioMed Ltd. Founded as a Northumbria University Spinout
ICURe Follow On Funding project initated
ICURe-funded COVID-19 multi-centre clinical study completes showing 100% patient detection
40% oversubscribed £1.4M equity investment (Mercia, SFC, US/UK/EU angels)
InnovateUK £1M project "Wheezsolve" awarded for asthma diagnosis application
PulmoBioMed Ltd. registers with US FDA and launches PBM-HALE™
UKCA, CE and ROW authorisation
Single step asthma test launch
What companies had to say about the Innovate UK ICURe programme?
"In May 2019, PulmoBioMed's team leveraged support from the ICURe NxNW program to conduct primary market validation research, engaging with Key Opinion Leaders from institutions like Harvard, Yale, and National Jewish Health at key events such as the American Thoracic Society and BIO Convention. They also discussed commercial applications with companies like Bosch, Roche, and Medtronic, and explored specialist uses with stakeholders such as ARA and Lawrence Livermore National Laboratory. Following over 141 significant conversations, an InnovateUK panel in July 2019 strongly recommended commercialisation via spinout. This led to winning a £299k InnovateUK Follow On funding bid in January 2020."
Professor Sterghios A. Moschos FRSC FIBMS
Founder, Director and CEO, PulmoBioMed Ltd.
Future Goals
Our company is seeking to rapidly grow its global offering of our unique deep lung breath sample collector through registrations in key territories such as the EU, South Africa, Middle East, East Asia, and the UK. At the same time, leading diagnostics assay manufacturers are evaluating their products in the utility for lung infection diagnosis.
We are growing the list of pharmaceutical companies and biotechs using our product to develop companion diagnostics for their novel therapeutics, and with the further support of InnovateUK are developing the first one-step asthma diagnosis and endotyping test.
We aim PulmoBioMed’s first and follow on products to become the reference solutions for lung disease diagnosis and discovery of new biomarkers that help medicine personalize and improve the efficacy of treatment.